Brachytherapy

Papers
(The TQCC of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications37
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial31
Prospective randomized trial of email and/or telephone reminders to enhance vaginal dilator compliance in patients undergoing brachytherapy for gynecologic malignancies30
Editorial Board29
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po26
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy25
Editorial Board18
Patient-controlled epidural analgesia, patient-controlled intravenous analgesia, and conventional intravenous opioids for gynecologic interstitial brachytherapy: A single-center retrospective study16
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data14
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost12
PO032411
PO024911
PO042511
MPP02 Presentation Time: 4:09 PM10
PPP02 Presentation Time: 10:39 AM10
PO022710
BP08 Presentation Time: 5:03 PM10
BP02 Presentation Time: 4:09 PM9
PO04179
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study9
PPP03 Presentation Time: 10:48 AM9
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM9
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy9
PRSOR02 Presentation Time: 12:05 PM8
PO358
PHSOR06 Presentation Time: 9:25 AM8
PO108
PSOR12  Presentation Time: 5:25 PM8
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM8
ABS21 Author Index8
PSOR03  Presentation Time: 12:10 PM8
PP18 Presentation Time: 4:15 PM8
PO217
PO357
PO207
PSOR8  Presentation Time: 12:05 PM7
PO937
GSOR04  Presentation Time: 12:15 PM7
PO477
PLEN03 Presentation Time: 1:45 PM6
PL02  Presentation Time: 1:45 PM6
GSOR05 Presentation Time: 2:50 PM6
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM6
PHSOR05  Presentation Time: 12:50 PM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
PO106
PHSOR06 Presentation Time: 10:25 AM6
MSPP03  Presentation Time: 4:20 PM6
PO256
PSOR02  Presentation Time: 4:35 PM6
PO086
GSOR14  Presentation Time: 11:35 AM6
PHSOR04  Presentation Time: 12:45 PM6
PO296
PO386
PP17 Presentation Time: 4:06 PM6
PO46  Presentation Time: 4:45 PM6
PO366
GSOR03 Presentation Time: 2:40 PM6
PO406
Table of Contents6
PP02  Presentation Time: 9:10 AM6
PO286
PP13 Presentation Time: 3:30 PM6
Editorial Board5
Table of Contents5
High-dose-rate brachytherapy for airway malignancy a single institution experience5
PL02 Presentation Time: 1:45 PM5
Determination of the optimal time for planning SAVI brachytherapy for APBI5
Masthead5
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
The case for risk-stratified IORT for early breast cancer5
MSOR12 Presentation Time: 8:55 AM5
MSOR11 Presentation Time: 8:50 AM5
Masthead5
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma5
PP05  Presentation Time: 5:06 PM5
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma5
PO04215
PO02345
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes5
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing4
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy4
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
Quantifying risk using FMEA: An alternate approach to AAPM TG-100 for scoring failures and evaluating clinical workflow4
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review4
Partial breast irradiation: An updated consensus statement from the American brachytherapy society4
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal4
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life4
A primer on time-driven activity-based costing in brachytherapy4
PSOR02 Presentation Time: 11:35 AM4
PO194
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts4
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy4
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up4
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction3
Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
PO1143
PO143
PP02  Presentation Time: 10:09 AM3
PO133
PO323
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer3
Skin Posters PO07013
Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer3
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM3
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
PO913
PO253
Inter-fractional variation of markers and applicators in single-implant high-dose-rate interstitial brachytherapy for gynecologic malignancies3
PP08 Presentation Time: 11:10 AM3
PO01093
PO01193
PO02413
PP31 Presentation Time: 11:50 AM3
PRSOR10 Presentation Time: 12:45 PM3
Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy3
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
PHSOR06  Presentation Time: 12:55 PM3
PO153
PO593
PO04243
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle3
PO02423
PLEN02 Presentation Time: 1:30 PM3
GSOR07 Presentation Time: 3:00 PM2
PO162
PSOR3  Presentation Time: 11:40 AM2
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer2
PP19 Presentation Time: 4:24 PM2
Systematic review of brachytherapy for symptom palliation2
PO33  Presentation Time: 10:30 AM2
PO03112
PO222
PP05  Presentation Time: 11:36 AM2
PRSOR08 Presentation Time: 12:35 PM2
PO02202
PHSOR07 Presentation Time: 10:30 AM2
MSPP05  Presentation Time: 4:40 PM2
PO422
PPP05 Presentation Time: 11:06 AM2
PO01102
GYN Posters PO012
PHSOR08 Presentation Time: 10:35 AM2
PO202
PO342
PO532
PP31 Presentation Time: 11:50 AM2
PSA: Declining utilization of prostate brachytherapy2
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting2
MSOR9 Presentation Time: 5:40 PM2
PP04  Presentation Time: 9:47 AM2
GSOR10 Presentation Time: 12:15 PM2
PO02582
PO862
MSOR11 Presentation Time: 5:50 PM2
PO522
PP02  Presentation Time: 8:29 AM2
PO532
PHSOR08  Presentation Time: 1:05 PM2
GSOR09 Presentation Time: 12:10 PM2
PO322
PO03202
PP04  Presentation Time: 11:27 AM2
PP25 Presentation Time: 4:20 PM2
PO492
PP01 Presentation Time: 10:00 AM2
PSOR7  Presentation Time: 12:00 PM2
PHSOR02 Presentation Time: 10:05 AM2
Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer2
PO40  Presentation Time: 4:45 PM2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
PO04082
PO522
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM2
MSOR04 Presentation Time: 10:20 AM2
PP14 Presentation Time: 3:39 PM2
PO27  Presentation Time: 7:40 AM2
MSOR05 Presentation Time: 10:25 AM2
PO192
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer2
PO122
PO02612
MSOR09 Presentation Time: 10:40 AM2
PHSOR02 Presentation Time: 10:05 AM1
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers1
PP08 Presentation Time: 11:10 AM1
Underutilization of brachytherapy for cervical cancer in the United States1
PO1081
Embracing a future of progress in gynecologic brachytherapy1
HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care1
PP08  Presentation Time: 10:40 AM1
Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy1
Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy1
GSOR05  Presentation Time: 12:20 PM1
Author Index1
PO02551
PO1191
MSOR7  Presentation Time: 5:15 PM1
MSOR03 Presentation Time: 10:10 AM1
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital1
PLEN03 Presentation Time: 1:45 PM1
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer1
Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach1
PHSOR04 Presentation Time: 10:15 AM1
Evaluating the relationship between vaginal apex “dog ears” and patterns of recurrence in endometrial cancer following adjuvant image guided vaginal cuff brachytherapy1
PP21 Presentation Time: 3:40 PM1
PO02471
PO1071
Effects of a novel form of intraoperative radiation therapy on quality of life among patients with early-stage breast cancer1
MSOR08 Presentation Time: 10:35 AM1
PO571
Radiation dose rate variations in different measurement scenarios after prostate 125I brachytherapy1
PO02441
PO1001
PO02561
PO171
ACR–ABS–ACNM–ASTRO–SIR–SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies1
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer1
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities1
Efficacy and safety of a 3D-printed applicator for vaginal brachytherapy in patients with central pelvic-recurrent cervical cancer after primary hysterectomy1
PP37 Presentation Time: 11:50 AM1
Feasibility of internal-source tracking with C-arm CT/SPECT imaging with limited-angle projection data for online in vivo dose verification in brachytherapy: A Monte Carlo simulation study1
MSS10  Presentation Time: 4:30 PM1
GSOR09  Presentation Time: 12:40 PM1
PO051
PO04061
PO091
PO291
Dosimetry and Monte Carlo modelling of the Papillon+ contact X-ray brachytherapy device1
PO311
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
Development and promotion of a 3D-printed phantom model for ultrasound-guided caudal block followed by intracavitary/interstitial brachytherapy for gynecological cancer1
PSOR05 Presentation Time: 11:50 AM1
PO1061
PO28  Presentation Time: 7:40 AM1
Artificial intelligence applications in brachytherapy: A literature review1
PO041
PSOR4  Presentation Time: 11:45 AM1
PO1031
Development and clinical implementation of simple needle attachment post placement interstitial template (SNAPP-IT) enabling a shorter, more direct needle path while preserving tumor visualization1
0.079539060592651